{
    "clinical_study": {
        "@rank": "95614", 
        "arm_group": [
            {
                "arm_group_label": "Bertilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Bertilimumab is a recombinant human IgG4 monoclonal antibody that neutralizes human eotaxin-1. Bertilimumab will be administered every other week for 4 weeks by IV infusion"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Phosphate buffered saline (PBS) placebo will be administered every other week for 4 weeks by IV infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "The study objectives are:\n\n        -  To evaluate the safety and clinical efficacy of Bertilimumab administered to subjects\n           with active moderate to severe UC\n\n        -  To evaluate the bioactivity, pharmacokinetics (PK) and pharmacodynamics (PD) effects of\n           Bertilimumab to subjects with active moderate to severe UC.\n\n      Study design:\n\n      This will be is a randomized, double blind, placebo-controlled, parallel group multi-center\n      study in adult subjects with active moderate to severe UC . Eligible subjects will be\n      randomly assigned to one of two treatment groups, bertilimumab or matching placebo.\n\n      The study will consist of three periods: a screening period of up to two weeks, a 4-week\n      double-blind treatment period, and approximately 9-week safety and efficacy follow-up\n      period.\n\n      Bertilimumab is a recombinant human IgG4 monoclonal antibody that neutralizes human\n      eotaxin-1 (eotaxin). Bertilimumab will be administered every other week for 4-weeks, by IV\n      infusion over 30 minutes."
        }, 
        "brief_title": "A Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Clinical Efficacy, and Pharmacokinetic Profile of Bertilimumab in Subjects With Active Moderate to Severe Ulcerative Colitis", 
        "condition": "Active Moderate to Severe Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, 18 to 70 years of age inclusive\n\n          -  Diagnosed with moderate to severely active UC per standard diagnostic criteria for a\n             minimum of 3 months.\n\n          -  High levels of eotaxin-1 in biopsied colon tissue of  \u2265100 pg/mL\n\n          -  Female subjects with childbearing potential must agree to use effective contraceptive\n             consistently from 30 days before screening through study completion.\n\n          -  Male subjects must agree to use effective contraceptive consistently throughout the\n             study.\n\n        Exclusion Criteria:\n\n          -  History of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy\n\n          -  Positive Clostridium difficile toxin stool assay\n\n          -  Tested positive for active/ latent mycobacterium tuberculosis (TB) infection\n\n          -  Pregnant or breast-feeding, or plan to become pregnant during the study\n\n          -  History of infection requiring administration of any IV antibiotic, antiviral or\n             antifungal medication within 30 days of Screening or any oral anti-infective agent\n             within 14 days of Screening.\n\n          -  Severe UC evidenced by the following signs of toxicity: heart rate >90 beats/min at\n             rest, temperature >37.8 degree, hemoglobin <10.5 g/dL\n\n          -  Ulcerative proctitis, defined as disease limited to less than 15 cm from the anal\n             verge\n\n          -  Subject diagnosed with:Crohn's disease;Indeterminate colitis (inability to\n             distinguish between UC and Crohn's disease);Microscopic colitis (collagenous or\n             lymphocytic colitis);Ischemic or infectious colitis;Clostridium difficile colitis\n             within 90 days of the screening visit;Parasitic disease within 90 days of the\n             screening visit\n\n          -  History of positive serology of hepatitis B or C, or human immunodeficiency virus\n             (HIV) infection\n\n          -  Congenital or acquired immunodeficiency (e.g., common variable immunodeficiency,\n             organ transplantation)\n\n          -  Active abuse of alcohol or drugs\n\n          -  known malignancy or history of malignancy that would reduce life expectancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671956", 
            "org_study_id": "C2a/BRT/UC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bertilimumab", 
                "intervention_name": "Bertilimumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 3, 2013", 
        "location": {
            "contact": {
                "email": "erang@szmc.org.il", 
                "last_name": "Eran Goldin, Prof.", 
                "phone": "02-6555916"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel", 
                    "zip": "91031"
                }, 
                "name": "Shaare Tzedek Medical Central"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Clinical Efficacy, and Pharmacokinetic Profile of Bertilimumab in Subjects With Active Moderate to Severe Ulcerative Colitis", 
        "other_outcome": {
            "measure": "Terminal half life of Bertilimumab", 
            "safety_issue": "No", 
            "time_frame": "Day 0,14,28 predose and 0.5 and 4 hours post dose and on day 35,42,66, 90"
        }, 
        "overall_contact": {
            "email": "erang@szmc.org.il", 
            "last_name": "Eran Goldin, Prof.", 
            "phone": "02-6555916"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "description": "A decrease in Mayo score from baseline of at least 3 points and at least 30% AND\nEither a decrease in the sub-score for rectal bleeding of at least 1 point, or rectal bleeding sub-score of 0 or 1.", 
            "measure": "Clinical response", 
            "safety_issue": "No", 
            "time_frame": "week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "day 0,14,28,35,42,66,90"
        }, 
        "source": "Immune Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immune Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}